Revolution Medicines, Inc. Additional Paid in Capital, Common Stock
Revolution Medicines, Inc. (RVMD) had Additional Paid in Capital, Common Stock of $6.58 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $6.58B.
- 2026-03-31: Additional Paid in Capital, Common Stock $4.82B.
- 2025-12-31: Additional Paid in Capital, Common Stock $4.50B.
- 2025-09-30: Additional Paid in Capital, Common Stock $4.10B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $6.58B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $4.82B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $4.50B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $4.10B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $4.06B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $4.03B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $4.00B 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.11B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.01B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $2.98B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.96B 10-K · filed 2025-02-26 |
| 2023-09-30 | $1.81B 10-Q · filed 2023-11-06 |
| 2023-06-30 | $1.80B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.72B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.39B 10-K · filed 2024-02-26 |
| 2022-09-30 | $1.33B 10-Q · filed 2022-11-07 |
| 2022-06-30 | $1.07B 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.06B 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.06B 10-K · filed 2023-02-27 |
| 2021-09-30 | $1.04B 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.03B 10-Q · filed 2021-08-11 |
| 2021-03-31 | $1.03B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $740.10M 10-K · filed 2022-02-28 |
| 2020-09-30 | $736.19M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $564.32M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $562.18M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $4.74M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |